Iodide

Iodide

SCHEMBL3056531

CCCCCCCC[S+]=C(N(CC)CC)N(CC)CC.[I-]

nearest known ligand 0.38

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG

The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 1/20 0.38
TSHR P16473 2/20 0.35
THRB P10828 1/20 0.35
CA12 O43570 3/20 0.33
CA1 P00915 3/20 0.33
CA9 Q16790 3/20 0.33
LMNA P02545 2/20 0.33
CA2 P00918 2/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
ALDH1A1 P00352 1/20 0.33
HSD17B10 Q99714 1/20 0.33
DNM1 Q05193 4/20 0.31
CES2 O00748 3/20 0.30
CES1 P23141 3/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Iodide SCHEMBL3049109 0.91 CA12 (0.34) MGLLCA12CA1CA9LMNA
Iodide SCHEMBL3259459 0.81 CA12 (0.31) MGLLCA12CA1CA9CA2
SCHEMBL3059900 0.79 RECQL (0.44) TSHRCA12CA1CA9CA2
Iodide SCHEMBL3047544 0.70 ALDH1A1 (0.36) ALDH1A1
SCHEMBL11039590 0.67 SPHK2 (0.42) TSHRTHRBLMNAMEN1KMT2A
SCHEMBL10528305 0.67 SPHK2 (0.42) TSHRTHRBLMNAMEN1KMT2A
Bromide SCHEMBL7046448 0.65 SPHK2 (0.41) TSHRTHRBLMNAMEN1KMT2A
Hydrochloric Acid SCHEMBL7529868 0.65 SPHK2 (0.41) TSHRTHRBLMNAMEN1KMT2A
Decane SCHEMBL23142599 0.59 TSHR (0.80) TSHRTHRBLMNAMEN1KMT2A
Decane SCHEMBL11227696 0.59 TSHR (0.80) TSHRTHRBLMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100222580-A1 Process For The Preparation Of Onium Alkylsulfates Having A Low Halide Content MERCK PATENT GMBH (DE) 2010-09-02 US disclosed
EP-1828142-B1 METHOD FOR PRODUCING ONIUM ALKYL SULFATES WITH A LOW HALOGENIDE CONTENT MERCK PATENT GMBH (DE) 2010-06-02 EP disclosed
EP-1828142-A1 METHOD FOR PRODUCING ONIUM ALKYL SULFATES WITH A LOW HALOGENIDE CONTENT Merck Patent GmbH (DE) 2007-09-05 EP disclosed
WO-2006063654-A1 METHOD FOR PRODUCING ONIUM ALKYL SULFATES WITH A LOW HALOGENIDE CONTENT MERCK PATENT GMBH (DE) 2006-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100222580-A1 Process For The Preparation Of Onium Alkylsulfates Having A Low Halide Content STS, MRPS35, ARSA MGLL 59/4885TSHR 2173/4885THRB 3239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.